The carrier was attached to the T cell targeting molecule, anti-CD3, and to different monoclonal antibodies that target a multiple myeloma antigen (BCMA, CS1, or CD38), increasing the poor half-life of conventional BiTEs. Here, TNFRSF17 is linked to plasma cell myeloma.